Search is Powered by Google
Multiple Sclerosis News

Yale Researchers Find New Trigger For Autoimmune Diseases

Main Category: Multiple Sclerosis
Also Included In: Immune System / Vaccines;  Lupus
Article Date: 29 Jul 2008 - 2:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:5 stars

4.51 (35 votes)

Health Professional:5 stars

4.64 (11 votes)

Article Opinions: 0 posts

Yale University researchers have discovered a new way that autoimmune diseases like multiple sclerosis (MS) can be triggered, they reported Monday in the journal Proceedings of the National Academy of Sciences.

Scientists have long known the molecule TGF-Beta (transforming growth factor Beta) plays a pivotal role in preventing T cells from launching an attack on the body's own tissues.

A team led by Richard Flavell, professor and chairman of Immunobiology at the Yale School of Medicine, investigated whether TGF-Beta might also influence activity of other immune system cells as well.

Flavell, an investigator for the Howard Hughes Medical Institute, and his colleagues engineered mice in which TGF-Beta was blocked at different places in the immune system. They found that when they blocked TGF-Beta in dendritic cells (DC's) the mice developed lesions on myelin sheathing of central nervous system cells, the hallmark of MS.

"Previous work suggested that the immune dysfunction seen when TGF-Beta is removed could all be explained by T cells," said Flavell. "Now we know that TGF-Beta control of DC's is important to prevent autoimmunity."

The PNAS study may explain why efforts to spur TGF-Beta activity only in T cells have had limited effects in treating autoimmune diseases, Flavell said.

The authors also speculated that bolstering TGF-Beta activity on dendritic cells might have a potentially therapeutic effect on patients with MS and other autoimmune diseases.

Authors on the study include Yasmina Laouar, Terrence Town, David Jeng, Elise Tran, Yisong Wan, and Vijay K. Kuchroo

The research was supported by National Institutes of Health.
Citation: PNAS July 28, 2008

Yale University




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
New Data Show Patients Using AVONEX Reported Less Sick Leave And Short-Term Disability Costs
04 Jun 2008
Results from an analysis assessing the differences in health benefits costs (HBCs) and lost time among employees suffering from multiple sclerosis (MS) being treated with injectable disease modifying therapies (DMTs) were...


Talking with Your Doctor image Talking with Your Doctor

Talking with your doctor can sometimes be difficult. Good health care, however, depends on an open dialogue between patients and doctors...

An MS Drug Back on the Market image An MS Drug Back on the Market

After being suspended from the market for safety reasons, natalizumab is again available for the treatment of multiple sclerosis. Safeguards are in place because of a small risk in developing a serious brain infection. Should you consider taking this drug...

View more videos...